Artificial intelligence using deep learning analysis of endoscopic ultrasonography images for the differential diagnosis of pancreatic masses.

Journal: Endoscopy
Published Date:

Abstract

BACKGROUND : There are several types of pancreatic mass, so it is important to distinguish between them before treatment. Artificial intelligence (AI) is a mathematical technique that automates learning and recognition of data patterns. This study aimed to investigate the efficacy of our AI model using endoscopic ultrasonography (EUS) images of multiple types of pancreatic mass (pancreatic ductal adenocarcinoma [PDAC], pancreatic adenosquamous carcinoma [PASC], acinar cell carcinoma [ACC], metastatic pancreatic tumor [MPT], neuroendocrine carcinoma [NEC], neuroendocrine tumor [NET], solid pseudopapillary neoplasm [SPN], chronic pancreatitis, and autoimmune pancreatitis [AIP]). METHODS : Patients who underwent EUS were included in this retrospective study. The included patients were divided into training, validation, and test cohorts. Using these cohorts, an AI model that can distinguish pancreatic carcinomas from noncarcinomatous pancreatic lesions was developed using a deep-learning architecture and the diagnostic performance of the AI model was evaluated. RESULTS : 22 000 images were generated from 933 patients. The area under the curve, sensitivity, specificity, and accuracy (95 %CI) of the AI model for the diagnosis of pancreatic carcinomas in the test cohort were 0.90 (0.84-0.97), 0.94 (0.88-0.98), 0.82 (0.68-0.92), and 0.91 (0.85-0.95), respectively. The per-category sensitivities (95 %CI) of each disease were PDAC 0.96 (0.90-0.99), PASC 1.00 (0.05-1.00), ACC 1.00 (0.22-1.00), MPT 0.33 (0.01-0.91), NEC 1.00 (0.22-1.00), NET 0.93 (0.66-1.00), SPN 1.00 (0.22-1.00), chronic pancreatitis 0.78 (0.52-0.94), and AIP 0.73 (0.39-0.94). CONCLUSIONS : Our developed AI model can distinguish pancreatic carcinomas from noncarcinomatous pancreatic lesions, but external validation is needed.

Authors

  • Takamichi Kuwahara
    Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Kazuo Hara
    First Department of Comprehensive Medicine, Division of Endocrinology and Metabolism, Jichi Medical University Saitama Medical Center, 1-847 Amanuma-cho, Omiya-ku, Saitama 330-8503, Japan.
  • Nobumasa Mizuno
    Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Shin Haba
    Department of Gastroenterology, Aichi Cancer Center Hospital, Aichi, Japan.
  • Nozomi Okuno
    Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Yasuhiro Kuraishi
    Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Daiki Fumihara
    Department of Gastroenterology, Aichi Cancer Center Hospital, Aichi, Japan.
  • Takafumi Yanaidani
    Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Sho Ishikawa
    Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Tsukasa Yasuda
    Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Masanori Yamada
    Dept. of Surgery, Kansai Medical University.
  • Sachiyo Onishi
    Department of Endoscopy, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Keisaku Yamada
    Department of Endoscopy, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Tsutomu Tanaka
    Department of Endoscopy, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Masahiro Tajika
    Department of Endoscopy, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Yasumasa Niwa
    Department of Endoscopy, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Rui Yamaguchi
    The Institute of Medical Science, The University of Tokyo, Shirokanedai 4-6-1, Minato-ku, Tokyo, 108-8639, Japan.
  • Yasuhiro Shimizu
    Department of Gastroenterological Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.